Results 191 to 200 of about 93,200 (346)

Use of the psoriasis epidemiology screening tool (PEST) to identify psoriatic arthritis in Bosnia and Herzegovina [PDF]

Jelena Petković-Dabić, Sanja Umičević-Šipka, Sonja Barišić, Saša Dabić   +3 more
openalex   +1 more source

Impact of adalimumab treatment on impairment of non‐professional activities in psoriasis patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non‐professional activities. This study investigates the effects of long‐term treatment with adalimumab regarding work ability, non‐professional activities, and health‐related quality of life in a large real‐word ...
Georgios Kokolakis, Sandra Philipp, Thomas Mosch, Björn Fritz, Robert Sabat   +4 more
wiley   +1 more source

Psoriatic Arthritis: Developments in 2025. [PDF]

Mediterr J Rheumatol
Spanopoulou C, Katsimbri P.
europepmc   +1 more source

The research potential of A20 in psoriatic arthritis. [PDF]

Front Immunol
Wan YW, Duan X, Jin Z, Chen H.
europepmc   +1 more source

Biogenesis of TNF‐α‐insights into proteostasis and inflammation

The FEBS Journal, EarlyView.
TNF‐α biogenesis, trafficking, and signalling are tightly and reciprocally coupled to cellular proteostasis systems, including ER chaperones and endoplasmic reticulum‐associated degradation. This bidirectional crosstalk determines whether TNF‐α responses are adaptive or proteotoxic.
Bailasan Haidar, Céline Philippe, Eric Chevet, Jiří Zahradník   +3 more
wiley   +1 more source

Therapeutic Windows Across the Psoriatic Arthritis Spectrum. [PDF]

Rheumatol Ther
Kang JH, Coates LC.
europepmc   +1 more source

Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database

, 2022
Husni ME, Eunice Chang, Broder MS, C Paydar, Katalin Bognar, Pooja Desai, Yuri M. Klyachkin, Ibrahim Khilfeh   +7 more
openalex   +1 more source

Study Protocol: Role of Intermittent Fasting on Disease Severity and Quality of Life in Psoriasis and Psoriatic Arthritis: A Single-Blind Parallel Group Randomized Control Trial

, 2023
Ashley Gray, Lucy Rose, D. Jolley, Bianka N. Bubic, Abraham M. Korman, Brittany Dulmage, Jennifer Sopkovich, Mark Bechtel, Jessica Kaffenberger, Benjamin H. Kaffenberger   +9 more
openalex   +2 more sources

Superior Clinical and Economic Value of IL‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

International Journal of Dermatology, EarlyView.
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco, Elena Ippoliti, Niccolò Gori, Giacomo Caldarola, Clara De Simone, Nicoletta Di Giorgi, Paulo Gabriel Longo, Marco Galluzzo, Luca Bianchi, Lorenzo Marcelli, Marina Talamonti, Maria Vittoria Cannizzaro, Lucia Di Nardo, Ketty Peris   +13 more
wiley   +1 more source

Drug development in psoriatic arthritis: a trialtrove-based landscape analysis (1999-2025). [PDF]

Front Immunol
Wang G, Li J, Su X, Fang Z, Xu Y, Zheng J, Liu H, Wang N, Huang L.   +8 more
europepmc   +1 more source